Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Clinical trial NCT06189209 · RECRUITING
Trial details
- NCT number
- NCT06189209
- Sponsor
- Rhizen Pharmaceuticals SA
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-04
- Primary completion
- 2026-12-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.